Search results
Results From The WOW.Com Content Network
A differentiating feature between this and more benign statin side effects is SAAM typically has a late onset. While muscle pain (myalgia) is seen in 9-20% of patients treated with statins, it typically occurs in the first month of treatment. SAAM has a later onset, occurring years after uncomplicated statin use.
Atorvastatin is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. [4] For the prevention of cardiovascular disease, statins are a first-line treatment. [4] It is taken by mouth. [4] Common side effects include joint pain, diarrhea, heartburn, nausea, and muscle pains. [4]
Using PREVENT to calculate the 10-year risk for developing heart disease, the researchers determined that some 40% fewer people would have met the criteria for a statin prescription.
Researchers tested simvastatin, later sold by Merck as Zocor, on 4,444 patients with high cholesterol and heart disease. After five years, the study concluded the patients saw a 35% reduction in their cholesterol, and their chances of dying of a heart attack were reduced by 42%. [12] [191] In 1995, Zocor and Mevacor both made Merck over US$1 ...
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.
Senior year of high school wasn’t a lot of fun for Tivaj Hopkins. He weighed 400 pounds, he skipped an amusement park trip because he was so big, and he couldn’t find anything nice to wear to ...
The data, published in the journal JAMA, showed patients who were obese and without diabetes experienced a 14% weight regain nearly a year after they switched to a placebo from an eight-month ...
[5] [6] [7] The study's authors estimated that the number needed to treat with rosuvastatin to prevent one cardiovascular event was 95 over two years, extrapolated to 25 over five years. The trial was stopped early, after just 1.9 years median duration, by the study's Independent Data Monitoring Board, because the interim results met the study ...